Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs S&P500 ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M), while S&P500 ETF trades at $767.81 (market cap $823.23B). The key difference: S&P500 ETF is far larger — about 842.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and S&P500 ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and S&P500 ETF for 206 Days on average.
| MRVI | SPY | |
|---|---|---|
Market Cap | $977.37M | $823.23B |
Volume | 2,742,564 | 55,376,546 |
Sector | Health | — |
52-Week High | $9.00 | $779.14 |
52-Week Low | $2.83 | $631.99 |
Typical Hold Time | 0 Days | 206 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SPY (SPDR S&P 500 ETF) trades at $778.05, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bullish trend with moving averages strongly supporting upward momentum, though oscillators remain neutral. The ETF maintains key support at $777 and resistance at $779. Recent news highlights S&P 500 valuation debates and sector rotations, with earnings growth expectations moderating from 35% in 2026 to 15% in 2027 according to Wall Street analysts.
The outlook for SPY remains positive given its broad market exposure and institutional support, though investors face risks from potential market volatility and slowing earnings growth. Current technical strength suggests near-term stability, but macroeconomic factors and sector-specific challenges could impact performance. The ETF's diversification provides resilience, but market-wide valuation concerns warrant cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
